Skip to main content
Clinical Trials/IRCT2016020526377N1
IRCT2016020526377N1
Completed
Phase 2

Clinical trial to evaluate the role of radioprotection effect of curcumin in peripheral blood lymphocytes of patients with differentiated thyroid carcinoma treated with Iodine-131, by micronucleus assay

Vice Chancellor for Research, Shahid Beheshti University of Medical Sciences0 sites20 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
differentiated thyroid carcinoma(DTC).
Sponsor
Vice Chancellor for Research, Shahid Beheshti University of Medical Sciences
Enrollment
20
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Vice Chancellor for Research, Shahid Beheshti University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • All patients with differentiated thyroid cancer (follicular, papillary or mixed type) don't received destroying dose (ablative dose) of radioiodine up to now; no palpable neck mass; thyroid pathology reported there is no invasion to capsular and lymph areas and blood vessels; body scan with 131\-I don’t show any functional tissue in regions other than the thyroid bed; thyroid cancer confirmed by biopsy; all patients have total thyroidectomy; TSH level before administration of radioiodine is higher than 30 IU/ML.
  • exclusion criteria: after treatment with 131 I if there is abnormal tissue absorption of iodine in other areas of the thyroid bed; if patients after taking the first capsule of curcumin had a headache and dizziness; patient will be excluded.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials